Prevalence of Symptoms in Female Fabry Disease Patients: a Case-control Survey

Overview

Journal J Inherit Metab Dis

Publisher Wiley

Date 2012 Mar 21

PMID 22431073

Citations 10

Authors

Machtelt G Bouwman

Saskia M Rombach

Erica Schenk

Annelies Sweeb

Frits A Wijburg

Carla E M Hollak

Gabor E Linthorst

Affiliations

Soon will be listed here.

Abstract

Background: Fabry disease (FD) is an X-linked lysosomal storage disorder, caused by a deficiency of α-galactosidase A. Several studies demonstrated that heterozygotes have symptoms such as acroparesthesia, abdominal pain and chronic fatigue. However, as these symptoms are aspecific and relatively common in the general population, it is important to compare the prevalence of these symptoms with an appropriate control group. The aim of this study was to explore the prevalence of signs and symptoms in FD females in comparison to a control group.

Methods: FD females and age-matched controls were approached to complete a questionnaire. This questionnaire was developed by the Dutch Fabry patient organisation (Fabry Support en Informatie Groep Nederland, FSIGN) with input from Fabry expert-physicians from the AMC. We compared the prevalence symptoms using Pearson's chi-square test. Bonferroni correction was used to correct for multiple comparisons.

Results: A total of 63 heterozygotes and 52 controls completed the questionnaire. Many symptoms were also common in controls. Yet, fatigue, palpitations, pains in hands and feet, joint pain, dizziness, loss of libido and proteinuria during pregnancy were more common in Fabry females (all p < 0.001).

Conclusion: In addition to acroparesthesia - fatigue, palpitations, dizziness, proteinuria during pregnancy, libido loss and joint pain are more prevalent in FD females as compared to a control group. Although, these symptoms are present in a significant proportion of normal controls they deserve further attention by treating physicians to better understand their significance, treatment and relationship with FD.

Citing Articles

Pregnancy outcomes of Fabry disease in Austria (PROFABIA)-a retrospective cohort-study.

Haninger-Vacariu N, Anastopoulos K, Aigner C, Sunder-Plassmann R, Gatterer C, Ponleitner M Orphanet J Rare Dis. 2024; 19(1):165.

PMID: 38637893 PMC: 11025160. DOI: 10.1186/s13023-024-03180-3.

Fabry Disease in Women: Genetic Basis, Available Biomarkers, and Clinical Manifestations.

Izhar R, Borriello M, La Russa A, Di Paola R, De A, Capasso G Genes (Basel). 2024; 15(1).

PMID: 38254927 PMC: 10815601. DOI: 10.3390/genes15010037.

Anderson-Fabry disease cardiomyopathy: an update on epidemiology, diagnostic approach, management and monitoring strategies.

Averbuch T, White J, Fine N Front Cardiovasc Med. 2023; 10:1152568.

PMID: 37332587 PMC: 10272370. DOI: 10.3389/fcvm.2023.1152568.

Review of Mechanisms, Pharmacological Management, Psychosocial Implications, and Holistic Treatment of Pain in Fabry Disease.

Rajan J, Ireland K, Johnson R, Stepien K J Clin Med. 2021; 10(18).

PMID: 34575277 PMC: 8472766. DOI: 10.3390/jcm10184168.

Fabry disease pain: patient and preclinical parallels.

Burand Jr A, Stucky C Pain. 2020; 162(5):1305-1321.

PMID: 33259456 PMC: 8054551. DOI: 10.1097/j.pain.0000000000002152.

References

Wang R, Lelis A, Mirocha J, Wilcox W . Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med. 2007; 9(1):34-45. DOI: 10.1097/gim.0b013e31802d8321. View

Bland J, Altman D . Multiple significance tests: the Bonferroni method. BMJ. 1995; 310(6973):170. PMC: 2548561. DOI: 10.1136/bmj.310.6973.170. View

Macdermot K, Holmes A, Miners A . Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001; 38(11):769-75. PMC: 1734754. DOI: 10.1136/jmg.38.11.769. View

Bouwman M, Hollak C, van den Bergh Weerman M, Wijburg F, Linthorst G . Analysis of placental tissue in Fabry disease with and without enzyme replacement therapy. Placenta. 2010; 31(4):344-6. DOI: 10.1016/j.placenta.2010.02.004. View

Parent E, Wax J, Smith W, Blaszyk H, Pinette M, Cartin A . Fabry disease complicating pregnancy. J Matern Fetal Neonatal Med. 2010; 23(10):1253-6. DOI: 10.3109/14767050903580391. View

Galanos J, Nicholls K, Grigg L, Kiers L, Crawford A, Becker G . Clinical features of Fabry's disease in Australian patients. Intern Med J. 2003; 32(12):575-84. DOI: 10.1046/j.1445-5994.2002.00291.x. View

Wilcox W, Oliveira J, Hopkin R, Ortiz A, Banikazemi M, Feldt-Rasmussen U . Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab. 2007; 93(2):112-28. DOI: 10.1016/j.ymgme.2007.09.013. View

Gupta S, Ries M, Kotsopoulos S, Schiffmann R . The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine (Baltimore). 2005; 84(5):261-268. DOI: 10.1097/01.md.0000178976.62537.6b. View

Schiffmann R, Warnock D, Banikazemi M, Bultas J, Linthorst G, Packman S . Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant. 2009; 24(7):2102-11. PMC: 2698092. DOI: 10.1093/ndt/gfp031. View

10.

Schiffmann R . Natural history of Fabry disease in males: preliminary observations. J Inherit Metab Dis. 2002; 24 Suppl 2:15-7; discussion 11-2. DOI: 10.1023/a:1012499119196. View

11.

Guffon N . Clinical presentation in female patients with Fabry disease. J Med Genet. 2003; 40(4):e38. PMC: 1735431. DOI: 10.1136/jmg.40.4.e38. View

12.

Macdermot K, Holmes A, Miners A . Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001; 38(11):750-60. PMC: 1734761. DOI: 10.1136/jmg.38.11.750. View

13.

Deegan P, Baehner A, Barba Romero M, Hughes D, Kampmann C, Beck M . Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet. 2005; 43(4):347-52. PMC: 2563231. DOI: 10.1136/jmg.2005.036327. View

14.

Germain D, Bruneval P, Tran T, Balouet P, Richalet B, Benistan K . Uneventful pregnancy outcome after enzyme replacement therapy with agalsidase beta in a heterozygous female with Fabry disease: A case report. Eur J Med Genet. 2010; 53(2):111-2. DOI: 10.1016/j.ejmg.2009.12.004. View

15.

Kobayashi M, Ohashi T, Sakuma M, Ida H, Eto Y . Clinical manifestations and natural history of Japanese heterozygous females with Fabry disease. J Inherit Metab Dis. 2008; 31 Suppl 3:483-7. DOI: 10.1007/s10545-007-0740-6. View

16.

Vedder A, Linthorst G, van Breemen M, Groener J, Bemelman F, Strijland A . The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis. 2007; 30(1):68-78. DOI: 10.1007/s10545-006-0484-8. View

17.

Wendt S, Whybra C, Kampmann C, Teichmann E, Beck M . Successful pregnancy outcome in a patient with Fabry disease receiving enzyme replacement therapy with agalsidase alfa. J Inherit Metab Dis. 2005; 28(5):787-8. DOI: 10.1007/s10545-005-0018-9. View

18.

Kalkum G, Macchiella D, Reinke J, Kolbl H, Beck M . Enzyme replacement therapy with agalsidase alfa in pregnant women with Fabry disease. Eur J Obstet Gynecol Reprod Biol. 2009; 144(1):92-3. DOI: 10.1016/j.ejogrb.2009.01.007. View

19.

Simon J . Low sexual desire--is it all in her head? Pathophysiology, diagnosis, and treatment of hypoactive sexual desire disorder. Postgrad Med. 2010; 122(6):128-36. DOI: 10.3810/pgm.2010.11.2230. View

20.

Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C . Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004; 34(3):236-42. DOI: 10.1111/j.1365-2362.2004.01309.x. View